Eli Lilly and Company

The stock remains in a powerful long-term uptrend, trading well above its 200-day average and not far from its 52-week high. The regime still favors momentum, though the gap to the high is narrower than earlier in the cycle, so shareholders should watch for consolidation after a major run.

Street sentiment stays constructive: the consensus rating is Buy, with 33 Buys, 9 Holds, and 3 Sells. Price targets have been pushed higher across multiple firms in recent weeks, with the consensus target at 1315.42 and the high at 1500, signaling continued upside expectations.

The earnings pattern is strong, with Lilly beating in 5 of the last 7 quarters and the most recent reported quarter topping estimates by 25.9%. Next-quarter expectations are high at 7.47 EPS, so the setup favors another solid print, but the bar is elevated and execution matters.

The pattern is mixed but leans to net selling. The only discretionary trade was an officer sale of 2,500 shares by Ilya Yuffa, while the rest were award grants and routine former-shareholder sales tied to Lilly Endowment. No meaningful insider buying has shown up recently.

Profitability is exceptional, led by an 82.8% gross margin and a 49.39% operating margin. Growth is still accelerating, with revenue up 55.5% year over year and earnings up 169.9%, while free cash flow reached $24.65 billion in fiscal 2025.

LLY still screens as a premium large-cap pharma name, supported by stronger growth and margins than most peers. The valuation remains rich versus the sector, so the market is paying for execution, pipeline depth, and durable obesity and diabetes leadership.